Thieler Law Corp, member of the Investor Attorney Network, is investigating whether certain officers and directors of Akorn Inc (NASDAQ: AKRX) violated securities laws in connection with certain financial statements.

The investigation seeks to discover if possible claims on behalf of purchasers of the securities of Akorn Inc (NASDAQ: AKRX) concerning whether a series of statements by Akorn Inc regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

On January 9, 2019, the Company revealed that it had received a warning letter from the U.S. Food and Drug Administration following an inspection of Akorn’s Decatur, Illinois manufacturing facility. The inspection revealed that the Company had failed to comply with multiple federal regulations pertaining to drug manufacturing.

Following this news, NASDAQ: AKRX fell $0.46 or over 11.6% to close at $3.48 on January 9, 2019.

Based in Lake Forest, Illinois, and founded in 1971 Akorn Inc develops, manufactures, and markets generic and branded prescription pharmaceuticals, over the counter consumer health products, and animal health pharmaceuticals in the United States and internationally.

If you purchased shares of Akorn Inc (NASDAQ: AKRX) on or before January 9, 2019, you should contact Thieler Law Corp at mail@thielerlaw.com or call +1 (619) 377 - 4324.

Thieler Law Corp purchases advertisements on search engines, social media sites and other websites. If you send us information, note that does not create an attorney-client relationship with the firm. Materials are provided for informational purposes only and do not constitute legal advice. We are only licensed to practice law in Germany. We are neither licensed nor qualified to render advice on US Federal or State law.

Thieler Law Corp

2534 State Street - Suite 406,

San Diego, CA 92101

by

email: mail@thielerlaw.com 

or

telephone at +1 (619) 377 - 4324

or

visit our website http://www.thielerlaw.com/ 

or

Facsimile: +1 (619) 785 – 3185